2.9357

8.30% 0.2257

Nexalin Technology Inc (NXL)

Overview News Price History Financials Discussions Forecast

Nexalin Technology Inc stock is traded at $2.9357, with a volume of 871.93K. It is up +8.30% in the last 24 hours and up +346.12% over the past month. Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Previous Close:

$2.71

Open:

$2.69

24h Volume:

871.93K

Relative Volume:

0.68

Market Cap:

$30.81M

Revenue:

$128.60K

Net Income/Loss:

$-4.60M

P/E Ratio:

-8.3877

EPS:

-0.35

Net Cash Flow:

$-3.74M

1W Performance:

+12.45%

1M Performance:

+346.12%

6M Performance:

+104.53%

1Y Performance:

+846.77%

1-Day Range:

$2.66

$3.05

1-Week Range:

$2.25

$3.40

52-Week Range:

$0.2528

$4.05

Nexalin Technology Inc Stock (NXL) Company Profile

Name

Nexalin Technology Inc

Sector

Healthcare (1181)

Industry

Medical Devices (155)

Phone

(832) 260-0222

Address

1776 YORKTOWN, HOUSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NXL's Discussions on Twitter

Nexalin Technology Inc Stock (NXL) Latest News

Nov 02, 2024

Nexalin regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia

Nov 02, 2024

Nexalin regains Nasdaq compliance with bid price rule - Investing.com India

Nov 02, 2024

Nov 01, 2024

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th - GlobeNewswire

Nov 01, 2024

Nexalin Technology : Regains Compliance with Nasdaq Continued Listing Requirements Form 8 K - Marketscreener.com

Nov 01, 2024

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - The Manila Times

Nov 01, 2024

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire

Nov 01, 2024

Oct 31, 2024

Nexalin technology's chief medical officer buys $1,095 in stock By Investing.com - Investing.com Canada

Oct 31, 2024

Oct 30, 2024

Nexalin technology's chief medical officer buys $1,095 in stock - Investing.com India

Oct 30, 2024

Oct 28, 2024

EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients - AOL

Oct 28, 2024

Nexalin Technology Announces Landmark Study on Alzheimer's - GlobeNewswire

Oct 28, 2024

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease - StockTitan

Oct 28, 2024

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED) - Benzinga

Oct 28, 2024

Oct 25, 2024

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire

Oct 25, 2024

Pre-Market Gains For Nexalin (NXL) Driven By Upcoming Clinical Trial - Stocks Telegraph

Oct 25, 2024

Oct 23, 2024

Nexalin trials Halo neurostimulation device in traumatic brain injury - Yahoo Finance

Oct 23, 2024

Oct 22, 2024

NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan

Oct 22, 2024

Nexalin Technology Announces Planned Clinical Trial - GlobeNewswire

Oct 22, 2024

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership - The Bakersfield Californian

Oct 22, 2024

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA - StockTitan

Oct 22, 2024

Oct 18, 2024

Mixed results for Nexalin’s transcranial alternating current stimulation trial - Yahoo Finance

Oct 18, 2024

Oct 17, 2024

New Study Shows Nexalin’s Deep Intracranial Frequency - GlobeNewswire

Oct 17, 2024

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients - StockTitan

Oct 17, 2024

EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study - Benzinga

Oct 17, 2024

Oct 14, 2024